Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as triamcinolone acetonide injectable
Triesence · 2 trials · 2 indications
A video image of the posterior segment structures of the eye was taken before instillation of the test product and after. An independent masked reader evaluated the images and graded the degree of visualization on a 5-point scale ranging from 1 to 4 and anchored at the ends by "Not Visible (0)" and "Clearly Delineated (4)." The mean difference was calculated, and a higher number indicated increased visibility.
Intraocular pressure (IOP) was measured by applanation tonometry in millimeters of mercury (mmHg). Surgical success was determined if IOP was \<21mmHg and 20% less than baseline IOP. Failure was defined as inability to meet criteria for success or IOP was less than 5mmHg.
| Arm | Type | Description |
|---|---|---|
| Triamcinolone | EXPERIMENTAL | Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal. |
| Treatment 1(Triesence) | EXPERIMENTAL | glaucoma surgery with 0.2cc Triesence adjunct. |
| Treatment 2 (balanced salt solution BSS) | ACTIVE_COMPARATOR | glaucoma surgery with balanced salt solution, the standard technique. |
| Name | Type | Description |
|---|---|---|
| Triamcinolone Acetonide Injectable Suspension | DRUG | Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal. |
| Triesence | DRUG | At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound. |
| balanced salt solution BSS | DRUG | At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure. |
Inclusion Criteria: * Patients planning to undergo pars plana vitrectomy with good vision in the non-surgery eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patients under 18. * Patients with previous vitrectomy, elevated intraocular pressure (IOP) and/or history...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Triesence is an investigational small molecule being studied for use in glaucoma. It is being evaluated for its ability to lower eye pressure during glaucoma surgery and improve surgical outcomes. The drug is in Phase 2 clinical development and is not yet approved for this use.
Triesence is being developed by Alcon Inc., a company traded under the ticker ALC. Alcon is conducting clinical research on the drug for the treatment of glaucoma.
Triesence is in Phase 2 clinical development. It is an investigational drug for glaucoma and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed.
Triesence has been studied in a completed Phase 2 clinical trial with the identifier NCT00853905. This trial enrolled 77 participants in the United States and evaluated the drug's use during glaucoma surgery to lower eye pressure and improve surgical results.
Triesence is a distinct investigational drug being developed by Alcon Inc. for glaucoma. It is being studied as an adjunct to glaucoma surgery, with the goal of reducing eye pressure and enhancing surgical outcomes.